Dual Time Point F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography Fusion Imaging (F-FDG PET/CT) in Primary Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Nov 29

PMID 31775675

Citations 2

Authors

Yoji Yamagishi

Tomomi Koiwai

Tamio Yamasaki

Takahiro Einama

Makiko Fukumura

Miyuki Hiratsuka

Takako Kono

Katsumi Hayashi

Jiro Ishida

Hideki Ueno

Hitoshi Tsuda

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV) at 60 min (SUV1) and SUV at 120 min (SUV2) (ΔSUV%) using dual time point F-fluorodeoxyglucose emission tomography/computed tomography (F-FDG PET/CT) in breast cancer.

Methods: Four hundred and sixty-four patients with primary breast cancer underwent F-FDG PET/CT for preoperative staging. ΔSUV% was defined as (SUV2 - SUV1) / SUV1 × 100. We explored the optimal cutoff value of SUV parameters (SUV1 and ΔSUV%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUV1 and ΔSUV% were analyzed by Cox's univariate and multivariate analyses.

Results: The optimal cutoff values of SUV1 and ΔSUV% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUV1 groups (P = 0.0003) and also between high and low ΔSUV% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUV1 was an independent prognostic factor (P = 0.0267) but ΔSUV% was not (P = 0.152). There was a weak correlation between SUV1 and ΔSUV% (P < 0.0001, R = 0.166). On combining SUV1 and ΔSUV%, the subgroups of high SUV1 and high ΔSUV% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002).

Conclusion: Dual time point F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUV1 and ΔSUV% was able to identify subgroups with worse prognosis more accurately than SUV1 alone.

Citing Articles

Clinical Impact of Dual Time Point F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer.

Einama T, Yamagishi Y, Takihata Y, Konno F, Kobayashi K, Yonamine N Cancers (Basel). 2022; 14(15).

PMID: 35954351 PMC: 9367454. DOI: 10.3390/cancers14153688.

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Balma M, Liberini V, Racca M, Laudicella R, Bauckneht M, Buschiazzo A Front Med (Lausanne). 2022; 9:881551.

PMID: 35492341 PMC: 9039137. DOI: 10.3389/fmed.2022.881551.

References

Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K . Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014; 105(11):1480-6. PMC: 4462379. DOI: 10.1111/cas.12525. View

Deng S, Zhang W, Zhang B, Chen Y, Li J, Wu Y . Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. PLoS One. 2015; 10(6):e0129028. PMC: 4454667. DOI: 10.1371/journal.pone.0129028. View

Groheux D, Hindie E, Delord M, Giacchetti S, Hamy A, de Bazelaire C . Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012; 104(24):1879-87. PMC: 3525816. DOI: 10.1093/jnci/djs451. View

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N . Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008; 38(4):250-8. DOI: 10.1093/jjco/hyn019. View

Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S . Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Breast. 2013; 22(5):958-63. DOI: 10.1016/j.breast.2013.05.003. View

Surov A, Meyer H, Hohn A, Winter K, Sabri O, Purz S . Associations Between [F]FDG-PET and Complex Histopathological Parameters Including Tumor Cell Count and Expression of KI 67, EGFR, VEGF, HIF-1α, and p53 in Head and Neck Squamous Cell Carcinoma. Mol Imaging Biol. 2018; 21(2):368-374. DOI: 10.1007/s11307-018-1223-x. View

Meyer H, Wienke A, Surov A . Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk. 2019; 19(6):e266-e272. DOI: 10.1016/j.clml.2019.03.005. View

Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G . Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008; 26(29):4746-51. DOI: 10.1200/JCO.2008.17.1496. View

Soussan M, Orlhac F, Boubaya M, Zelek L, Ziol M, Eder V . Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One. 2014; 9(4):e94017. PMC: 3983104. DOI: 10.1371/journal.pone.0094017. View

10.

Choi J, Lim I, Noh W, Kim H, Seong M, Jang S . Prediction of tumor differentiation using sequential PET/CT and MRI in patients with breast cancer. Ann Nucl Med. 2018; 32(6):389-397. DOI: 10.1007/s12149-018-1259-7. View

11.

Simsek D, Sanli Y, Kulle C, Karanlik H, Kilic B, Kuyumcu S . Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer. Nucl Med Commun. 2017; 38(8):694-700. DOI: 10.1097/MNM.0000000000000694. View

12.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

13.

Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y . Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer. Ann Nucl Med. 2015; 29(10):854-60. PMC: 4666280. DOI: 10.1007/s12149-015-1013-3. View

14.

Lim D, Lee J . Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study. Nucl Med Mol Imaging. 2017; 51(4):323-330. PMC: 5721088. DOI: 10.1007/s13139-017-0480-y. View

15.

Dowsett M, Nielsen T, AHern R, Bartlett J, Coombes R, Cuzick J . Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22):1656-64. PMC: 3216967. DOI: 10.1093/jnci/djr393. View

16.

Rasmussen G, Vogelius I, Rasmussen J, Schumaker L, Ioffe O, Cullen K . Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta Oncol. 2015; 54(9):1408-15. DOI: 10.3109/0284186X.2015.1062539. View

17.

Groheux D, Giacchetti S, Moretti J, Porcher R, Espie M, Lehmann-Che J . Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2010; 38(3):426-35. DOI: 10.1007/s00259-010-1640-9. View

18.

Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50. PMC: 2684553. DOI: 10.1093/jnci/djp082. View

19.

Matthies A, Hickeson M, Cuchiara A, Alavi A . Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002; 43(7):871-5. View

20.

Lodge M, Lucas J, Marsden P, Cronin B, ODoherty M, Smith M . A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999; 26(1):22-30. DOI: 10.1007/s002590050355. View